Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. The company is headquartered in San Diego, California and currently employs 314 full-time employees. The company went IPO on 2020-07-10. The Company’s approach to cell and gene therapies is based on its genetic editing platforms, including its non-viral piggyBac DNA Delivery System, Cas-CLOVER Site-Specific Gene Editing System and nanoparticle and hybrid gene delivery technologies. Its P-MUC1C-ALLO1 is an allogeneic CAR-T product candidate with the potential to treat a range of solid tumor indications, including breast and other epithelial-derived cancers. Its product candidate, P-PSMA- ALLO1, is being developed for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). Its product candidate P-BCMA-ALLO1 and P-BCMACD19-ALLO1 is developed for patients with multiple myeloma. Its P-CD19CD20-ALLO1 is an allogeneic, CAR-T product candidate in preclinical development for B cell leukemia and lymphoma indications.